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The Intangible Magic of Celebrity Marketing
Drug industry insiders share their tips on using celebrities to expand markets
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A
s the Hispanic world well 
knows, the word in Spanish for 
advertising is ‘propaganda’, 
its meaning derived literally from the 
propagation of the faith, the antithesis 
of science’s Enlightenment ideals. 
The old word somehow seems perfect 
for describing the new world of drug 
promotion and its growing use of 
the famous face. Like the catholic 
cardinals of the 17th century, many 
of the feted celebrities of the 21st are 
now engaged in spreading the word. 
Now, as then, the religion promises 
miraculous breakthroughs, wonder 
cures, and sometimes even eternal life. 
The difference is that this time around, 
the stars are earning fat fees from 
the marketing departments of giant 
pharmaceutical companies. And if the 
latest revelations from industry insiders 
are anything to go by, their hefty 
investments in celebrity selling are well 
worth it.
Celebrity Selling
The epicentre of this phenomenon 
is of course the United States, where 
companies routinely hire celebrities to 
attract attention to the latest drugs and 
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the diseases that go with them. Pﬁ  zer 
famously paid presidential hopeful Bob 
Dole to promote awareness of erectile 
dysfunction as sildenaﬁ  l (Viagra) 
was hitting the market. Wyeth hired 
supermodel Lauren Hutton to hawk 
hormone replacement therapy and 
menopause. GSK contracted football 
star Ricky Williams to sell social anxiety 
disorder, helping make paroxetine 
(Paxil)—brieﬂ  y—the world’s top-
selling antidepressant. Even the dead 
are raising awareness, with the estate 
of Errol Flynn now enlisted to help 
promote cardiovascular disease as a 
household name [1]. The celebrity, 
living or dead, becomes integral to a 
drug marketing strategy that includes 
paid advertising and aggressive public 
relations campaigns that can produce 
media appearances on the likes of 
Oprah and The Today Show. According 
to celebrity brokers, the star’s 
remuneration package, though always 
conﬁ  dential, can range from $20,000 to 
$2 million. 
‘A partnership between a celebrity 
and a brand has an intangible sort 
of magic’, writes a senior marketing 
executive at Amgen, in an extremely 
candid piece published recently in an 
industry trade magazine [2]. Amgen 
is the Californian biotech ﬁ  rm that 
hired handsome ‘West Wing’ star Rob 
Lowe to help market an anti-infection 
drug. Lowe was reportedly paid more 
than $1 million by Amgen, though 
there is speculation that part of the fee 
might ﬂ  ow to charity [3]. In her report, 
Amgen’s Osnat Benshoshan shares 
some thoughtful tips with her peers 
among the pharmaceutical marketing 
fraternity: ‘use an A-list celebrity’; ﬁ  nd 
a ‘news-hook’ that links the celebrity 
and your product; develop some simple 
messages; and make sure the celebrity 
delivers them at every appearance.
Benshoshan then reveals why on-
air talk-show appearances on ‘top-tier 
media venues’ like The Rosie Show 
can be better forums for celebrities 
than straight advertisements, which 
are governed by regulations. ‘The 
great advantage over advertising is 
that the airtime is practically free, 
and there is no fair balance to worry 
about’ she writes [2]. The downside 
with a media interview, she laments, 
is that compared to a scripted ad, ‘the 
situation is less controllable. It can be 
tricky for the celebrity to ensure that 
all product messages are delivered….’ 
Her other big tip for drug-makers is to 
rate your prospective celebrity with a 
‘Q score’, a measure of their likeability 
and recognisability with the public. 
Apparently Rob Lowe’s Q score was 
high with women over ﬁ  fty, a key target 
of the Amgen campaign [3].
Another recent report from 
within the industry draws on public 
opinion survey data to guide drug 
company marketers on the selection 
and ‘effective use’ of celebrity 
spokespersons [4]. The survey was 
conducted by a Seattle ﬁ  rm called 
NexCura Inc., in partnership with 
the trade magazine that published 
the study. The major ﬁ  ndings echo 
the insights of the Amgen executive 
about credibility, and underline 
the importance of your star being 
perceived as generally trustworthy, and 
speciﬁ  cally knowledgeable about the 
condition on which they are hired to 
speak. Perhaps not surprisingly, the 
survey found that people diagnosed as 
suffering chronic conditions were far 
more attentive to celebrity messages on 
health than the general public. 
The issue of credibility is important, 
the NexCura Inc. researchers point out, 
because ‘the credibility rating is used as 
a surrogate for “buying” behavior’—an 
intermediate measure of whether the 
star can persuade people to request 
the target drug from their doctor. The 
survey found that Bob Dole was still the 
most recognisable celebrity marketer 
with the United States public, but that 
the skater Dorothy Hamill—currently 
promoting Merck’s arthritis medication 
rofecoxib (Vioxx)—took the lead in the 
credibility stakes. Signiﬁ  cantly though, 
almost three-quarters of those surveyed 
were correctly able to identify Bob 
Dole with Pﬁ  zer’s Viagra, despite the 
fact that the advertisements in which 
he appeared were ‘unbranded’ ads for 
erectile dysfunction. The researchers 
concluded by recommending that 
drug companies choose a celebrity 
with personal experience of the 
target condition; choose someone 
trustworthy—perhaps a newsreader or 
sports ﬁ  gure; and choose someone who 
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will promote a single cause or brand 
rather than multiple ones. 
Ironically, the NexCura survey also 
found two-thirds of medical consumers 
agreed with the proposition that 
celebrities were ‘just doing it for the 
money and can’t be trusted’.
The Trouble with Celebrity Selling
The ﬁ  rst problem here is that the 
public is often not even informed 
whether a celebrity is receiving money 
from a drug company. In the case of TV 
star Rob Lowe, there was no mandated 
requirement for him to disclose his link 
with Amgen when appearing on media 
shows watched by millions. According 
to one industry insider familiar with the 
case, who did not want to be named, 
‘it depended if he remembered to say 
it, and whether he was asked’. The 
media’s failure to disclose relevant 
conﬂ  icts of interest when covering 
healthcare is well established [5]. 
When Frasier star Kelsey Grammer 
and his wife were promoting irritable 
bowel syndrome on top-rating TV 
shows, viewers thought the pair were 
speaking on behalf of an independent 
foundation. In fact the couple’s fee 
had ﬂ  owed from GSK, which was at 
that time preparing the market for 
alosetron (Lotronex), a controversial 
new drug that carried modest beneﬁ  ts 
and severe side effects, including 
possible death [6].
Equally as serious is the lack of any 
formal requirement for stars or media 
outlets to spell out drug side effects 
along with beneﬁ  ts when celebrities 
are pushing products or conditions. 
Lauren Hutton can be quoted, in 
magazine articles read by millions of 
readers, as saying, ‘My No. 1 secret is 
estrogen’ without any need for her, 
or the magazine, to list the dangers 
of the hormone replacement therapy 
made by her sponsor [7]. But perhaps 
most troubling is the way celebrities, 
with their star power, can help to 
fundamentally shift the public debate 
about major health problems. 
While Prince Charles’s companion 
Camilla Parker Bowles takes no 
money from drug companies, she did 
choose to make an important public 
statement about the bone condition 
osteoporosis at an international 
conference funded by Lilly, a company 
promoting a medication for the 
condition [8]. Camilla’s call for 
early intervention and greater use of 
expensive tests and technologies for 
the primary prevention of osteoporosis 
drew on materials sponsored by the 
pharmaceutical industry, and was 
synchronised with simplistic industry 
marketing messages. Camilla’s high-
proﬁ  le intervention at a drug company 
sponsored forum, albeit unwittingly, 
helps keep the focus on biochemical 
causes of, and biochemical solutions to, 
the much wider public health problem 
of fractures. Moreover these simple 
marketing messages undermine the 
complexity of the cost-effectiveness 
arguments that are central to any 
rational debate about the equitable 
distribution of health care resources. 
Other high-proﬁ  le ﬁ  gures attending 
the same conference eagerly accepted 
Lilly money, and one, former Texas 
Governor Ann Richards, blatantly 
promoted Lilly’s drug during an 
interview on CNN’s Larry King Show 
just days later [8].
The Future of Celebrity Selling 
With pharmaceutical marketing, it is 
clear that nothing short of a Vatican 
II-style reform is required, though 
there are already encouraging signs 
of change. Scientiﬁ  c journals are 
slowly disentangling themselves from 
unhealthy industry inﬂ  uence over 
what they publish, and public access 
to clinical trial data is daily a closer 
reality [9]. However, a less distorted 
scientiﬁ  c record about healthcare 
products is meaningless without 
regulations on how important science 
is communicated to the public. 
Celebrities paid by drug companies to 
promote drugs, or ‘raise awareness’ 
about disease, should be subject to 
the same rules as direct-to-consumer 
advertising, which would mean 
prohibition in many nations and much 
more fulsome disclosure in the United 
States than is currently the case. At 
the very least, public disclosure of a 
product’s risks and beneﬁ  ts, and the 
magnitude of the celebrity’s fee, should 
be mandatory and routine. Let’s see 
what that does to their Q rating.  
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